A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.

2023-509862-39-00 Protocol ARV-BA-001 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 23 Feb 2024 · End 4 Apr 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol ARV-BA-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 14
Countries 1
Sites 1

Healthy volunteers

Key facts

Sponsor
Echo Pharmaceuticals B.V.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
23 Feb 2024 → 4 Apr 2024
Decision date (initial)
2024-02-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

VersionLevelCodeTermSystem organ class
26.0 LLT 10088820 Clinical trial healthy volunteer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Echo Pharmaceuticals B.V.

Sponsor organisation
Echo Pharmaceuticals B.V.
Address
Robert Boyleweg 4
City
Leiden
Postcode
2333 CG
Country
Netherlands

Scientific contact point

Organisation
Echo Pharmaceuticals B.V.
Contact name
Clinical Research Manager

Public contact point

Organisation
Echo Pharmaceuticals B.V.
Contact name
Clinical Research Manager

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 14 1
Rest of world 0

Investigational sites

Hungary

1 site · Ended
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2024-02-23 2024-04-04 2024-02-26 2024-03-07

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-05 Hungary Acceptable
2024-02-19
2024-02-19